Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2020-02-14
Buyer: Sykehusinnkjøp HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 400000 NOK
Award criteria: Lowest price

Technical requirements: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for parenteral special pharmaceutical preparations (LIS 2001c). The competition includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List. A new need has arisen after the contracts were signed for contracts for the delivery of Cellcept for infusion (ATC code L04AA06) as the selected supplier has announced that the delivery of their product cannot be maintained.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for parenteral special pharmaceutical preparations (LIS 2001c). The competition includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List.
A new need has arisen after the contracts were signed for contracts for the delivery of Cellcept for infusion (ATC code L04AA06) as the selected supplier has announced that the delivery of their product cannot be maintained.
Due to this, LIS intends to enter into contracts between the regional health trusts (the contracting authorities) and Roche Norge AS (the supplier) as an additional contract to LIS 2001c, i.e. the scope and duration of the contract will follow the mentioned procurement
(Hereunder access to extension and cancellation), without the announcement of a new competition for this active ingredient.
LIS has explored the market situation and is of the opinion that it is not possible to hold a new competition or that a supplier other than Roche Norge AS can deliver the product in the same contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could foresee. LIS therefore believes that there are grounds to make the procurement without a competition. Refer to the public procurement regulation § 21-5, cf. § 21-2, cf. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.
LIS requests that any objections to this intention are submitted before the expiry of the waiting period, set at 20.2.2020. If no objections are received, a contract will be signed after the waiting period has expired.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for parenteral special pharmaceutical preparations (LIS 2001c). The competition includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List. After signing of contracts, a new need has arisen to sign contracts for the delivery of Cellcept for infusion (ATC code L04AA06) as the selected supplier has announced that the delivery of their product cannot be maintained.


Winner: Roche Norge AS
Award value: 400000